Barclays analyst Andrew Mok lowered the firm’s price target on Elevance Health (ELV) to $327 from $358 and keeps an Overweight rating on the shares following the Q2 report. The firm revised the company’s model post the earnings print.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Target downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Argus downgrades Elevance Health to Hold on ongoing profit pressures
- Elevance Health downgraded to Hold from Buy at Argus
- Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts
- Insider Moves: Seagate, Elevance, Appian, AeroVironment, Box